152 related articles for article (PubMed ID: 38596674)
21. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
22. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
23. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
24. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study.
Yu Y; He Z; Ouyang J; Tan Y; Chen Y; Gu Y; Mao L; Ren W; Wang J; Lin L; Wu Z; Liu J; Ou Q; Hu Q; Li A; Chen K; Li C; Lu N; Li X; Su F; Liu Q; Xie C; Yao H
EBioMedicine; 2021 Jul; 69():103460. PubMed ID: 34233259
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
[TBL] [Abstract][Full Text] [Related]
26. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
Wang H; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
[TBL] [Abstract][Full Text] [Related]
27. Radiomics of
Mu W; Tunali I; Gray JE; Qi J; Schabath MB; Gillies RJ
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1168-1182. PubMed ID: 31807885
[TBL] [Abstract][Full Text] [Related]
28. PET/CT-based deep learning grading signature to optimize surgical decisions for clinical stage I invasive lung adenocarcinoma and biologic basis under its prediction: a multicenter study.
Zhong Y; Cai C; Chen T; Gui H; Chen C; Deng J; Yang M; Yu B; Song Y; Wang T; Chen Y; Shi H; Xie D; Chen C; She Y
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):521-534. PubMed ID: 37725128
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
30. An integrated model combined intra- and peritumoral regions for predicting chemoradiation response of non small cell lung cancers based on radiomics and deep learning.
Ma Y; Li Q
Cancer Radiother; 2023 Dec; 27(8):705-711. PubMed ID: 37932182
[TBL] [Abstract][Full Text] [Related]
31. Comparison of different criteria for estimating major pathological response in resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Liu X; Wang C; Jiang Y; Lin D
Ann Diagn Pathol; 2024 Apr; 69():152268. PubMed ID: 38301396
[TBL] [Abstract][Full Text] [Related]
32. Deep learning for lung cancer prognostication: A retrospective multi-cohort radiomics study.
Hosny A; Parmar C; Coroller TP; Grossmann P; Zeleznik R; Kumar A; Bussink J; Gillies RJ; Mak RH; Aerts HJWL
PLoS Med; 2018 Nov; 15(11):e1002711. PubMed ID: 30500819
[TBL] [Abstract][Full Text] [Related]
33. Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 and pathological remission in neoadjuvant immunotherapy of NSCLC.
Sun C; Ma X; Meng F; Chen X; Wang X; Sun W; Xu Y; He H; Zhang H; Ma K
Neoplasia; 2024 Apr; 50():100977. PubMed ID: 38354688
[TBL] [Abstract][Full Text] [Related]
34. A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study.
Tong H; Sun J; Fang J; Zhang M; Liu H; Xia R; Zhou W; Liu K; Chen X
Front Immunol; 2022; 13():859323. PubMed ID: 35572597
[TBL] [Abstract][Full Text] [Related]
35. A short-term follow-up CT based radiomics approach to predict response to immunotherapy in advanced non-small-cell lung cancer.
Gong J; Bao X; Wang T; Liu J; Peng W; Shi J; Wu F; Gu Y
Oncoimmunology; 2022; 11(1):2028962. PubMed ID: 35096486
[TBL] [Abstract][Full Text] [Related]
36. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
37. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis of neoadjuvant chemoimmunotherapy in stage III non-small cell lung cancer.
Liu W; Zhang T; Zhang Q; Li L; Xu C
BMC Pulm Med; 2022 Dec; 22(1):490. PubMed ID: 36582007
[TBL] [Abstract][Full Text] [Related]
39. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
40. Pretreatment ultrasound-based deep learning radiomics model for the early prediction of pathologic response to neoadjuvant chemotherapy in breast cancer.
Yu FH; Miao SM; Li CY; Hang J; Deng J; Ye XH; Liu Y
Eur Radiol; 2023 Aug; 33(8):5634-5644. PubMed ID: 36976336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]